MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
0.5291
+0.0097
+1.87%
Opening 12:48 08/10 EDT
OPEN
0.5150
PREV CLOSE
0.5194
HIGH
0.5400
LOW
0.5150
VOLUME
64.94K
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
0.2760
MARKET CAP
18.59M
P/E (TTM)
-0.3661
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SKYE last week (0803-0807)?
Weekly Report · 7h ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 3d ago
VOO vs VTI: Are You Owning the Wrong Vanguard ETF?
TipRanks · 4d ago
Weekly Report: what happened at SKYE last week (0727-0731)?
Weekly Report · 08/03 09:13
Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It 
TipRanks · 07/29 19:05
Weekly Report: what happened at SKYE last week (0720-0724)?
Weekly Report · 07/27 09:14
Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims 
TipRanks · 07/23 19:14
Weekly Report: what happened at SKYE last week (0713-0717)?
Weekly Report · 07/20 09:13
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.